NEW ORAL ANTICOAGULANTS: IS THAT PLAUSIBLE TO IMPLEMENT THE DATA FROM INTERNATIONAL TRIALS TO RUSSIAN POPULATION?

Abstract

Aim. To compare, in what extent are the patients with atrial fibrillation (AF), included into three large randomized clinical trials (RCT) of the new oral anticoagulants (NOAC), comparable with Russian patients with AF. Material and methods. We revealed the results of the published Russian registries showing clinical and anamnestic data on the patients with all types of AF. The research done with the contents of journals and the list of Russian epidemiological studies in cardiology. Totally 6 papers selected that match with the requirements of contemporary registry. Results. Patients included into RCT, differ by the severity of the disease. In RELY-AF and ARISTOTLE study patients were quite similar, however ROCKET-AF was significantly different by the severity of included patients diseases. Of 6 selected Russian registries, two were outpatients (RECVAZA-Ryazan and RECVAZA-Yaroslavl), two registries of specialized units (PROFIL and the registry based on the FMSVU), and acute myocardial infarction (LIS-1) and stroke (LIS-2) registries. These patients are the most similar with those included into ROCJET-AF. However, by the range of parameters that characterize the severity of pathology, they even worse comparing to those with ROCKET-AF. The patients included into FSMSU registry and PROFIL are more relevant to those included into RELY-AF and ARISTOTLE.Conclusion. Currently there are no large registries of AF in Russian Federation. In general, the Russian "portrait" of AF-patient has worse course of the disease, which those included to RCT: ROCKET-AF, RELY- AF and ARISTOTLE, that makes it very important to implement the data obtained in these three large-scale RCT in Russian population with care.

Keywords

• фибрилляция предсердий
• регистр
• новые оральные антикоагулянты
• клинико-анамнестическая характеристика